Market Cap | 139.58K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -4.61M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -40.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -92.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -98.00% |
Recommedations | - | Quick Ratio | 0.00 | Shares Outstanding | 7.22M | 52W Low Chg | 33.00% |
Insider Own | 11.67% | ROA | -532.88% | Shares Float | 6.70M | Beta | 0.17 |
Inst Own | - | ROE | - | Shares Shorted/Prior | 2.05K/1.99K | Price | 0.04 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 10,916 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 2 | Change | 0.00% |
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.